Ascendia

  MARKET NEWS

Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM Platform to Target the Human Ribosome for Therapeutic Benefit
Tonix Pharmaceuticals Announces Initiation of Enrollment in MGH Phase 2 POWER Study of Intranasal Potentiated Oxytocin for the Treatment of Pediatric Obesity
ZyVersa Therapeutics Announces Publication That Demonstrates Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation From EMA for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation
Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for the Company’s Proprietary Drug for Obstructive Sleep Apnea Treatment
Ardena & RiboPro Forge Strategic Alliance to Support the RNA Revolution With End-to-End Manufacturing of Advanced mRNA & LNP Solutions

  FEATURED EDITORIAL

  COMPANY PROFILE

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical, and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. Click here for more.

CLICK IMAGE FOR THIS WEEK’S FEATURED VIDEO

CLICK IMAGE FOR THIS WEEK’S FEATURED VIDEO

  EXCLUSIVE ONLINE CONTENT

 

Acquisition of Solus BioTech Expands Croda's Specialized Pharma Business in Asia

Acquisition of Solus BioTech Expands Croda's Specialized Pharma Business in Asia

Croda International Plc recently announced it has acquired Solus BioTech, a global leader in premium, biotechnology-derived materials, from Solus Advanced Materials…..

LIfT BioSciences Heralds a New Era of Affordable Effective Cancer Cell Therapies Simply Produced From iPSCs

LIfT BioSciences Heralds a New Era of Affordable Effective Cancer Cell Therapies Simply Produced From iPSCs

LIfT BioSciences recently announced successful proof-of-concept production of its patented cancer killing alpha neutrophils from induced….

Caribou Biosciences Announces -Million Equity Investment From Pfizer

Caribou Biosciences Announces $25-Million Equity Investment From Pfizer

Caribou Biosciences, Inc. recently announced Pfizer Inc. has made a $25-million equity investment in the company. Pfizer purchased 4,690,431 of Caribou common shares at a price of….

Adare Pharma Solutions Announces Divestiture of Postbiotics Pioneer Adare Biome to dsm-firmenich

Adare Pharma Solutions Announces Divestiture of Postbiotics Pioneer Adare Biome to dsm-firmenich

Adare Pharma Solutions recently announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing.  Since these devices….

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Overcoming the Knowledge Gap: Long-Acting Injectables & Implantables

WHITEPAPER - Overcoming the Knowledge Gap: Long-Acting Injectables & Implantables

What’s In This Whitepaper?

Long-acting products, such as Long-Acting Injectables (LAIs) and implantables, have gained significant traction in recent years, revolutionizing patient treatment and medication adherence. By reducing the number of doses required, long-acting products improve patient compliance and eliminate …

WHITEPAPER - PLGA Nanoparticles - Bridging the Gap From R&D to GMP

WHITEPAPER - PLGA Nanoparticles - Bridging the Gap From R&D to GMP

Poly(lactic-co-glycolic acid) (PLGA) has emerged as a promising material for drug delivery and biomedical applications. Its exceptional biocompatibility, customizable degradation and release properties, and versatility have led to its approval by regulatory bodies like the FDA and EMA.…

WHITEPAPER - Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion & Polyvinyl Alcohol

WHITEPAPER - Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion & Polyvinyl Alcohol

 

Solubility of the active pharmaceutical ingredient (API) in an oral formulation is critical for absorption from the gastrointestinal (GI) tract and the intended therapeutic effect. Ensuring that an API has the necessary solubility can be challenging for drug developers …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 2 – Drug Delivery
August 9 – Injection Devices